MedTrace Logo

The Bioseal Vascular Study

NCT02094885 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2018-03-08

Study results available
· View outcomes & findings →

Summary

To evaluate the clinical utility of Bioseal as an adjunct to control bleeding during elective vascular surgery.

Conditions

  • Cardiovascular Bleeding
  • Vascular Bleeding
  • Hemorrhage

Interventions

OTHER

Manual Compression

BIOLOGICAL

Bioseal Fibrin Sealant

Sponsors & Collaborators

  • Guangzhou Bioseal Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Ethicon, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Kocharian, MD, PhD · Ethicon, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-01
Primary Completion
2014-11-01
Completion
2014-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094885 on ClinicalTrials.gov